0ELV.L - Guerbet SA
| Chiusura precedente | 16,42 |
| Aperto | 16,56 |
| Denaro | 0,00 x N/D |
| Lettera | 0,00 x N/D |
| Min-Max giorno | 16,56 - 16,88 |
| Intervallo di 52 settimane | 15,32 - 25,00 |
| Volume | |
| Media Volume | 3.172 |
| Capitalizzazione | 209,686M |
| Beta (5 anni mensile) | 0,69 |
| Rapporto PE (ttm) | 6,51 |
| EPS (ttm) | 2,58 |
| Prossima data utili | N/D |
| Rendimento e dividendo (forward) | N/D (N/D) |
| Data ex dividendo | N/D |
| Stima target 1A | N/D |
GlobeNewswireGuerbet: Changes in Guerbet's Board of Directors
Changes in Guerbet's Board of Directors Appointment of Didier Izabel as Chair of the Board of DirectorsAppointment of Pascale Auger as an Independent DirectorRenewal of three directorships Villepinte, 26 May 2023: Guerbet (FR0000032526 GBT), a world specialist in contrast products and solutions for medical imaging, announces, following the Annual General Meeting of 26 May 2023 and a Board of Directors meeting held on the same day: the appointment of Didier Izabel as Chair of the Board of Directo
- GlobeNewswire
Guerbet: Q1 2023 Revenue
Q1 2023 RevenueQuarterly activity • Revenue: €179.8 million, down slightly by 1.3% at CER • Dynamic activity in EMEA (+7.3% at CER), increase in Asia (+2.2% at CER), expected drop in the Americas (-17.1% at CER) Annual objectives reaffirmed• 2023 revenue up more than 5% on a like-for-like basis and at CER• Restated EBITDA margin : around 11% in 2023,before returning to a level higher in 2024 than in 2021 (14.4%) Villepinte, Thursday, April 20, 2023 - Guerbet (FR0000032526 GBT), a global speciali
- GlobeNewswire
Guerbet: 2022 annual results
2022 annual results Activity Annual revenue: €753.3 million, up 2.9% (-1.1% at CER1)Steady momentum in Asia and for Interventional Imaging; negative impact of production delays at the Raleigh site Profitability in line with expectations The restated EBITDA margin2 is 13.8%, at the top of the range of 13% to 14% announced last October 2023 outlook Revenue: expected growth above 5% on a like-for-like basis and at CER1Restated EBITDA margin3 expected around 11% before returning in 2024 to a level h
- GlobeNewswire
Guerbet: 2022 revenue
2022 revenue Activity Annual revenue: €753.3 million, up +2.9% (-1.1% at CER1); production lags at the Raleigh site weighed on activity Profitability 2022 EBITDA margin: confirmation of the announced range of 13% to 14% (excluding extraordinary costs for the optimization of the operational structure and changes in the sales model in China) Outlook 2023 revenue: expected growth above 5% on a like-for-like basis and at CER Villepinte, February 9, 2023: Guerbet (FR0000032526 GBT), a global speciali
- GlobeNewswire
Guerbet: 2023 Strategic Priorities
2023 Strategic Priorities Diagnostic Imaging: increase EluciremTM sales and strengthen international positionsInterventional Imaging: prioritise Lipiodol sales with the development of innovative indications Artificial Intelligence: execution of the roadmap for the emergence of a major AI player dedicated to medical imaging in oncology Villepinte, 16 January 2023: Guerbet (FR0000032526 GBT), a global specialist in contrast agents and solutions for medical imaging has announced its strategic prior
- GlobeNewswire
Guerbet: Intrasense opens its share capital to the Guerbet Group, which announces its intent to file a voluntary tender offer under the same price conditions
Intrasense opens its share capital to the Guerbet Group, which announces its intent to file a voluntary tender offer under the same price conditions Montpellier, France, January 11, 2023 at 6:00 PM CET Intrasense (FR0011179886 - ALINS), a specialist in medical imaging software solutions ("Intrasense" or the "Company") announces that the Guerbet Group (FR0000032526 - GBT) has acquired a 39% stake in its share capital through a reserved share capital increase for a total amount of 8.8 million euro
- GlobeNewswire
Guerbet: Guerbet announces a change in governance for its Artificial Intelligence projects
Guerbet announces a change in governance for its Artificial Intelligence projects Villepinte, November 3rd, 2022: Guerbet today announced an agreement with Merative, formalizing the termination of their collaboration signed in July 2018. Guerbet today announced an agreement with Merative formalizing the termination of their collaboration initiated in July 2018. This partnership aimed to design, develop and market software solutions to help diagnose and monitor liver and prostate cancers. The ter
- GlobeNewswire
Guerbet: Revenue at September 30, 2022
Revenue on September 30, 2022 Faster growth in Q3 2022 Revenue: +5.1% at CER1 (€187 million)Very dynamic activity in Asia (+18.4%) and within MRI (+17.3%)Cumulative revenue at 9 months: +0.8% at CER (€569.2 million) Update of 2022 financial targets Impact of prioritizing EluciremTM production at the Raleigh plantLike-for-like revenue growth below 2% at CER,2022 EBITDA margin between 13% and 14% (excluding extraordinary costs to optimize the operating structure and change the sales model in China
- GlobeNewswire
Guerbet obtains one million euros of public funding from Bpifrance (France 2030 investment plan) for a project developing artificial intelligence for the early detection of pancreatic cancer
Guerbet obtains one million euros of public funding from Bpifrance (France 2030 investment plan) for a project developing artificial intelligence for the early detection of pancreatic cancer Villepinte, 26 September 2022 – 18:00: Guerbet (GBT) obtains one million euros of public funding through a call for projects concerning the acceleration strategy in digital health via the France 2030 investment plan. The early diagnosis of pancreatic cancer is a major public health concern. The presentation
- GlobeNewswire
Guerbet announces U.S. Food and Drug Administration (FDA) approval of Elucirem™ (Gadopiclenol)
Guerbet announces U.S. Food and Drug Administration (FDA) approval of Elucirem™ (Gadopiclenol) FDA approval of EluciremTM (NDA 216986) was granted after priority review, a designation assigned to applications for drugs that provide significant improvements in the safety or effectiveness of the treatment, diagnosis, or prevention of serious conditions compared to available therapies.In the approved indications, a contrast-enhanced MRI examination using Elucirem™ requires half the gadolinium dose
- GlobeNewswire
Guerbet: 2022 half-year results
2022 half-year results Slight business growth H1 revenue: €371.1 million, up 2.2% (-1.3% at CER1); sustained momentum in Asia and activity in the United States impacted by labor market tensions affecting a production site Profitability maintained H1 EBITDA2: €50.5 million; margin of 13.9% of revenue (excluding extraordinary expenses for optimization of the operational structure and changes in the sales model in China) 2022 objectives confirmed Expected revenue growth of between 2% and 4% on a li
- GlobeNewswire
Guerbet: Revenue at June 30, 2022
H1 2022 sales Slight business growth €371.1 M, up 2.2% from 1st half of 2021(-1.3% at constant exchange rates)Strong sales in Asia Sales in the US negatively affected by labor market tensions involving a production site2022 guidance Villepinte, Thursday, July 21, 2022: Guerbet (FR0000032526 GBT), a global specialist in contrast agents and solutions for medical imaging, reports its revenue for the first half of 2022. As of June 30, Group sales totaled €371.1 M, up 2.2% compared with H1 2021 (€363
- GlobeNewswire
Guerbet receives EMA acceptance of EluciremTM as the Brand Name for Gadopiclenol
Guerbet receives EMA acceptance of EluciremTM as the Brand Name for Gadopiclenol. Villepinte (France), June 13 2022 (8:30 CET) – Guerbet (FR0000032526 GBT), a global leader in medical imaging, announces today that EluciremTM, the proposed Guerbet brand name for Gadopiclenol, has been accepted by the European Medicines Agency (EMA). Gadopiclenol is an investigational macrocyclic gadolinium-based contrast agent. "We are very pleased with the acceptance of EluciremTM as the brand name for Gadopicle